Recombinant CD274 (Avelumab Biosimilar) 抗体
-
- 抗原 See all CD274 (Avelumab Biosimilar) products
- CD274 (Avelumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This CD274 (Avelumab Biosimilar) antibody is un-conjugated
- 应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Avelumab Biosimilar, Human PD-L1 Monoclonal Antibody
- 特异性
- The in vivo grade avelumab biosimilar specifically binds to the programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1.
- 产品特性
- Recombinant Humanized IgG1 Monoclonal Antibody.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The anti-human PD-L1 monoclonal antibody avelumab biosimilar was produced in the avelumab biosimilar Chinese Hamster Ovary (CHO) stable cell line.
- 亚型
- IgG1 kappa
-
-
- 应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by avelumab.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- CD274 (Avelumab Biosimilar)
- Abstract
- CD274 (Avelumab Biosimilar) 产品
- 物质类
- Biosimilar
- 背景
-
What is Avelumab biosimilar research grade? Avelumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1), with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab is used for the treatment of several kinds of carcinoma. Avelumab biosimilar uses the same protein sequences as the therapeutic antibody of Avelumab.
PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Avelumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
-